

Attorney Docket No. 0069-03

**REMARKS**

Claims 17-29 have been canceled without prejudice, and new claims 30 and 31 have been added. Claims 30-31 are now pending for the Examiner's consideration.

New claims 30 and 31 correspond to canceled claims 26 and 27 rewritten in independent form.

Applicants respectfully request reconsideration and withdrawal of the outstanding objections and rejections, in light of the foregoing amendments and following remarks.

The Office Action does not include any rejections of claims 26 and 27, even though these claims are part of the group of claims listed in the Office Action Summary as being finally rejected. By the present amendments, Applicants have rewritten claims 26 and 27 in independent form, including all of the limitations of claim 17 from which they depended. These rewritten claims are now new claims 30-31. Since there are no outstanding rejections, Applicants believe claims 26 and 27 are allowable.

**Conclusion**

Applicants believe all claims are now in condition for allowance. Should there be any issues that have not been addressed to the Examiners satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicant hereby petitions), please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: February 19, 2004

Stephen D. Prodnuk  
Stephen D. Prodnuk  
Attorney For Applicants  
Registration No. 43,020

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-3087  
Fax: (858) 678-8233